Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Dr. Lindsley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2010
Washington University in St. Louis School of MedicineClass of 2008, M.D., Ph.D.
Certifications & Licensure
MA State Medical License 2011 - 2026
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 20 citationsSingle-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.Mariela Cortés-López, Paulina Chamely, Allegra G Hawkins, Robert F Stanley, Ariel D Swett
Cell Stem Cell. 2023-09-07 - 51 citationsGerm line predisposition variants occur in myelodysplastic syndrome patients of all ages.Simone Feurstein, Amy M Trottier, Noel Estrada-Merly, Matthew Pozsgai, Kelsey McNeely
Blood. 2022-12-15 - 12 citationsTransplant for TP53-mutated MDS and AML: because we can or because we should?Jurjen Versluis, R Coleman Lindsley
Hematology. American Society of Hematology. Education Program. 2022-12-09
Abstracts/Posters
- Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS StudyR. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant AbstractR. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
